mHealth

What is mHealth?

As defined by a National Institutes of Health Consensus group, mHealth is the use of mobile and wireless devices to improve health outcomes, healthcare services and health research. Because medication management is critical to outcomes and because the true point of care is wherever the patient doses, we are focused on medication telemanagement as a key part of mHealth. Because of the importance of mobility to well-being, we refer to our patents as the "mMed" patent portfolio.

The mHealth Opportunity

As it becomes more urgent to control healthcare costs by improving treatment outcomes of the aging population, there is great opportunity for the ever-growing number of mobile communication users who also are medication users- to play a bigger role in improving their health and the quality of their lives. Improved outcomes also will yield great benefits to society.

There are 321 million wireless subscriber connections in the U.S. There are 321 million wireless subscriber connections in the U.S.

research2guidance

Did you know?

New Directions Technology Consulting is the exclusive market developer for the mMed patent portfolio of five granted U.S. patents relating to technology that when deployed could take medication telemanagement to patients wherever they are at any time.


Interested in learning more?

Schedule a call or receive more information


The "Other" Drug Problems

Achieving or maintaining health and controlling related costs are often dependent on adherence to medication regimens and protocols, for which patients or their caregivers, not healthcare professionals, are responsible. Medication telemanagement can obviously help patients comply with instructions.

Maintaining control of prescription drugs throughout the entire supply chain can help ensure adequate training, and help curtail abuse, improper storage, diversion and improper disposal. View a full list of benefits.


The cost of non-adherence

cost of non-adherence: Annual U.S. cost estimates for non-adherence range from $100-$300 billion Annual U.S. cost estimates for non-adherence range from $100-$300 billion

more health benefits worldwide would result from improving adherence to existing treatments than developing any new medical treatments. more health benefits worldwide would result from improving adherence to existing treatments than developing any new medical treatments.

"Medication Adherence: Making the Case for Increased Awareness," co-authored by Hayden B. Bosworth, Ph.D., Duke University Medical Center, and the National Consumers League

More about the cost of non-adherence

Recent advances in pharmaceutical treatments for many chronic and acute health problems are well known. Left untreated or undertreated, these conditions often lead to decreased quality of life,increased risk of death and higher costs. The effectiveness of medications and their long-term benefits depend on patients' following instructions that they are given for prescribed treatment.

Medication non-adherence is an enormous burden to the world's healthcare system. Annual U.S. cost estimates for non-adherence range up to $300 billion. This includes costs for related additional doctor visits, emergency-room treatments, hospital admissions and additional medicines. A World Health Organization report states that because the magnitude of medication non-adherence is so alarming, more health benefits worldwide would result from improving adherence to existing treatments than developing any new medical treatments.

(From "Medication Adherence: Making the Case for Increased Awareness," co-authored by Hayden B. Bosworth, Ph.D., Duke University Medical Center, and the National Consumers League) Link to www.nclnet.org


Many of the advances are specialty drugs, including biotech products that are administered by the patients. These products are often very costly and require special handling and control through the supply chain, including in patients' hands, to avoid waste from mishandling.

Looking for ways to cut the cost of medication non-adherence and manage specialty pharma products?

The mMed patent portfolio of granted patents relating to technology could help meet the challenge.
Learn more about possible solutions to medication non-adherence covered by the patent portfolio.